GLP-1 drugs may lower serious liver risks compared to DPP-4 inhibitors in type 2 diabetes

People with type 2 diabetes often worry about their liver health. A recent look at existing data compared two common drug classes: GLP-1 receptor agonists and DPP-4 inhibitors. These medicines help control blood sugar but doctors wanted to know if one was safer for the liver. The review found that the GLP-1 group had a lower risk of developing cirrhosis or other serious liver problems. The numbers showed a 15 percent reduction in risk for those taking the GLP-1 drugs. This finding comes from twelve different studies involving adults with diabetes. It is important to note that all the studies looked at were observational. This means they watched people over time rather than assigning them to groups randomly. Because of this, other factors like lifestyle or how often patients saw a doctor could have influenced the results. The researchers could not rule out these other influences. Also, the studies did not have enough people to fully prove the effect on advanced liver disease. So, while the results are promising, they should be seen as a strong hint rather than final proof. More research is needed to confirm these findings with stronger evidence.